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BACKGROUND
In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated defi-
ciency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained 
adhesion of von Willebrand factor multimers to platelets and microthrombosis, 
which result in thrombocytopenia, hemolytic anemia, and tissue ischemia. Caplaciz-
umab, an anti–von Willebrand factor humanized, bivalent variable-domain-only 
immunoglobulin fragment, inhibits interaction between von Willebrand factor multi-
mers and platelets.
METHODS
In this double-blind, controlled trial, we randomly assigned 145 patients with TTP to 
receive caplacizumab (10-mg intravenous loading bolus, followed by 10 mg daily 
subcutaneously) or placebo during plasma exchange and for 30 days thereafter. The 
primary outcome was the time to normalization of the platelet count, with discon-
tinuation of daily plasma exchange within 5 days thereafter. Key secondary outcomes 
included a composite of TTP-related death, recurrence of TTP, or a thromboembolic 
event during the trial treatment period; recurrence of TTP at any time during the trial; 
refractory TTP; and normalization of organ-damage markers.
RESULTS
The median time to normalization of the platelet count was shorter with caplacizumab 
than with placebo (2.69 days [95% confidence interval {CI}, 1.89 to 2.83] vs. 2.88 days 
[95% CI, 2.68 to 3.56], P = 0.01), and patients who received caplacizumab were 1.55 
times as likely to have a normalization of the platelet count as those who received 
placebo. The percentage of patients with a composite outcome event was 74% lower 
with caplacizumab than with placebo (12% vs. 49%, P<0.001). The percentage of 
patients who had a recurrence of TTP at any time during the trial was 67% lower with 
caplacizumab than with placebo (12% vs. 38%, P<0.001). Refractory disease devel-
oped in no patients in the caplacizumab group and in three patients in the placebo 
group. Patients who received caplacizumab needed less plasma exchange and had 
a shorter hospitalization than those who received placebo. The most common ad-
verse event was mucocutaneous bleeding, which was reported in 65% of the patients 
in the caplacizumab group and in 48% in the placebo group. During the trial treat-
ment period, three patients in the placebo group died. One patient in the caplaciz-
umab group died from cerebral ischemia after the end of the treatment period.
CONCLUSIONS
Among patients with TTP, treatment with caplacizumab was associated with faster 
normalization of the platelet count; a lower incidence of a composite of TTP-related 
death, recurrence of TTP, or a thromboembolic event during the treatment period; 
and a lower rate of recurrence of TTP during the trial than placebo. (Funded by 
Ablynx; HERCULES ClinicalTrials.gov number, NCT02553317.)
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A cquired or immune-mediated thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangi-
opathy that is characterized by thrombocytopenia 
and hemolytic anemia. Autoantibodies inhibit ac-
tivity of the von Willebrand factor–cleaving pro-
tease ADAMTS13 (a disintegrin and metallo-
proteinase with a thrombospondin type 1 motif, 
member 13), which leads to platelet consumption 
in von Willebrand factor–platelet aggregates and 
microvascular thrombosis.1 The ensuing tissue 
ischemia and multiorgan dysfunction may result 
in thromboembolic events and death. A diagnosis 
of TTP is based on clinical presentation and labo-
ratory results and is confirmed by documentation 
of severe ADAMTS13 deficiency, with ADAMTS13 
activity levels of less than 10%.2 Current treatment 
consists of daily plasma exchange,3 to replenish 
functional ADAMTS13 and remove von Willebrand 
factor and autoantibodies, and immunosuppres-
sive therapy (e.g., glucocorticoids and rituximab) 
to suppress anti-ADAMTS13 autoantibodies.4 Re-
fractory disease, which develops in approximately 
one in six patients and is characterized by platelet 
counts that either do not increase at all or increase 
very slowly, is associated with poor outcomes.
Patients may die or have irreversible neurologic 
deficits before a response to treatment occurs. An 
episode of TTP may result in long-term conse-
quences, such as cognitive deficits, depression, 
arterial hypertension, and premature death.5 A 
major challenge is the persistent risk of life-
threatening recurrences, which are termed exac-
erbations if they occur within 30 days after the 
last plasma exchange and relapses if they occur 
more than 30 days after the last plasma ex-
change. Most recurrences occur during the first 
year or two, but they can occur as late as 10 or 
20 years after an episode of TTP.6,7 Longitudinal 
testing has established persistent or recurrent 
ADAMTS13 deficiency as a strong risk factor for 
recurrence.6,8-11
Caplacizumab, a humanized, bivalent, variable-
domain-only immunoglobulin fragment (Nano-
body, Ablynx), targets the A1 domain of von 
Willebrand factor, preventing interaction with the 
platelet glycoprotein Ib-IX-V receptor12 and the en-
suing microvascular thrombosis. A phase 2 trial 
showed the efficacy of caplacizumab as compared 
with placebo with respect to the time to normal-
ization of the platelet count, the incidence of re-
currence of TTP during the treatment period,13 
the percentage of patients in whom refractory 
disease developed,14 and the incidence of major 
thromboembolic events.15 A subgroup of patients 
who had persistent ADAMTS13 deficiency had a 
relapse soon after treatment with caplacizumab 
was stopped, which suggests that monitoring of 
ADAMTS13 could be useful to guide the continu-
ation of therapy.13 In the phase 3 HERCULES trial 
(A Phase III Double-Blind, Randomized, Parallel 
Group, Multicenter Placebo-Controlled Trial to 
Study the Efficacy and Safety of Caplacizumab in 
Patients with Acquired Thrombotic Thrombocy-
topenic Purpura), we sought to confirm the po-
tential role of caplacizumab in the treatment of 
TTP by comparing caplacizumab with placebo 
with respect to the time to normalization of the 
platelet count and the risk of death and compli-
cations caused by thrombotic events and organ 
damage. The trial also evaluated the potential of 
caplacizumab to reduce the risk of recurrence by 
allowing for treatment to continue until immuno-
suppressive therapy resolved the underlying auto-
immune disease.
Me thods
Patients
Adults (≥18 years of age) and, at some sites, chil-
dren 2 to 18 years of age were eligible for par-
ticipation if they had TTP that was diagnosed on 
the basis of clinical presentation (the presence of 
both thrombocytopenia and microangiopathic 
hemolytic anemia with schistocytes seen on blood 
smear) and if they had received exactly one plasma-
exchange treatment. Severe ADAMTS13 deficiency 
was not an eligibility criterion. Patients were ex-
cluded if they had suspected thrombotic micro-
angiopathies that were not associated with TTP, 
such as hemolytic uremic syndrome, or if they had 
congenital TTP.
Trial Design and Oversight
We conducted this randomized, double-blind, pla-
cebo-controlled trial at 92 sites worldwide (see 
the Supplementary Appendix, available with the 
full text of this article at NEJM.org). The institu-
tional review board or ethics committee at each 
participating site approved the protocol, which is 
available at NEJM.org, and all the patients provided 
written informed consent. The sponsor designed 
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the trial in collaboration with the external steering 
committee. An independent data and safety mon-
itoring board monitored the trial. An independent 
adjudication committee whose members were un-
aware of the trial-group assignments reviewed all 
potential major thromboembolic events and as-
sessed the relatedness of deaths to TTP. The re-
sults of the trial were critically evaluated and 
interpreted by the authors, who reviewed and 
revised the manuscript. The authors vouch for the 
accuracy and completeness of the data and analy-
ses and for the fidelity of the trial to the protocol. 
No one who is not an author contributed to the 
writing of the manuscript.
Trial Assignments
Patients were randomly assigned to receive par-
enteral caplacizumab or placebo, in addition to 
standard-of-care treatment for TTP, defined in 
the protocol as daily plasma exchange (at 1 to 
1.5 times the estimated plasma volume, until at 
least 2 days after normalization of the platelet 
count) and glucocorticoids (prednisone or pred-
nisolone at a dose of ≥1 mg per kilogram of body 
weight per day during the daily plasma-exchange 
period and continuing for the first week after 
the end of the daily plasma-exchange period). Sub-
sequently, treatment with glucocorticoids could 
be tapered at the discretion of the investigator, 
with the aim of stopping glucocorticoid treatment 
completely within 30 days after the last plasma 
exchange. Other immunosuppressive therapy was 
allowed in accordance with clinical practice at 
each site. Randomization was stratified according 
to neurologic involvement (baseline Glasgow Coma 
Scale score of ≤12 vs. >13, on a scale ranging 
from 3 to 15, with lower scores indicating worse 
mental status). Patients received an intravenous 
loading dose of caplacizumab (10 mg) or placebo 
before the start of the first plasma exchange after 
randomization. Subsequent doses (10 mg) were 
administered subcutaneously, once daily, until 
30 days after the last daily plasma exchange. Ad-
ministration of caplacizumab or placebo could be 
extended for a maximum of 28 days beyond the 
30 days, guided by risk factors for recurrence of 
TTP, such as persistent severe ADAMTS13 defi-
ciency, and was to be accompanied by immuno-
suppressive therapy that was adjusted as needed. 
In the event of disease recurrence (i.e., a new de-
crease in the platelet count that necessitated the 
reinitiation of daily plasma exchange) at any time 
during the treatment period, patients were switched 
to open-label treatment with caplacizumab; how-
ever, the initial trial-group assignment remained 
concealed. The trial included a 28-day follow-up 
period after the end of the treatment period. Any 
recurrences during this follow-up period were 
managed with the standard of care, without re-
initiation of the trial regimen.
Outcome Measures
The primary outcome was the time to a response, 
which was defined as the time from the first 
intravenous administration of caplacizumab or 
placebo to normalization of the platelet count 
(i.e., a platelet count of at least 150,000 per cubic 
millimeter), with discontinuation of daily plasma 
exchange within 5 days thereafter. The four key 
secondary outcomes, which were hierarchically 
ranked on the basis of clinical relevance, were 
the following: a composite of TTP-related death, 
recurrence of TTP, or a major thromboembolic 
event during the trial treatment period; recur-
rence of TTP at any time during the trial, includ-
ing the follow-up period; refractory TTP (defined 
by the lack of a doubling of the platelet count 
after 4 days of treatment and a lactate dehydro-
genase level that remained above the upper limit 
of the normal range); and the time to normaliza-
tion (i.e., to a level below the defined upper limit 
of the normal range) of three organ-damage mark-
ers (lactate dehydrogenase, cardiac troponin I, and 
serum creatinine). A recurrence was defined as 
a new decrease in the platelet count that neces-
sitated the reinitiation of plasma exchange after 
normalization of the platelet count had occurred. 
An exacerbation was defined as a recurrence that 
occurred within 30 days after the last plasma 
exchange. A relapse was defined as a recurrence 
that occurred more than 30 days after cessation 
of plasma exchange.
Outcomes that were not part of the hierarchy 
included the number of days of plasma exchange 
and the volume of plasma exchanged, the dura-
tion of stay in an intensive care unit and in the 
hospital, mortality rate, pharmacodynamic and 
pharmacokinetic variables, and immunogenicity. 
Safety assessments were performed throughout 
the course of the trial and included evaluation of 
vital signs, physical examinations, clinical labo-
ratory testing, and 12-lead electrocardiography. 
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Adverse events were coded according to the Medi-
cal Dictionary for Regulatory Activities, version 20.0.
ADAMTS13 activity was measured at a central 
laboratory at baseline, every week during the treat-
ment period beginning with the first day after the 
end of daily plasma exchange, and twice during 
the follow-up period. In patients who had a re-
currence of TTP while receiving caplacizumab or 
placebo, ADAMTS13 activity was measured at the 
time of the recurrence and then weekly beginning 
with the first day after plasma exchange during 
treatment with open-label caplacizumab.
Statistical Analysis
We estimated that with a sample of 132 patients, 
the trial would have 80% power to detect a median 
time to normalization of the platelet count that 
was 40% shorter with caplacizumab than with 
placebo, using a log-rank test at a 5% significance 
level and assuming a 10% dropout rate. We calcu-
lated that this sample size would also provide 83% 
power to detect a rate of the first key secondary 
outcome (i.e., a composite of TTP-related death, 
recurrence of TTP, or a major thromboembolic 
event during the trial treatment period) that was 
20% lower in the caplacizumab group than in 
the placebo group, using a chi-square test with 
a large sample approximation and a 5% signifi-
cance level. All efficacy analyses were conducted 
in the intention-to-treat population (which includ-
ed all patients who underwent randomization), 
whereas the safety and immunogenicity analyses 
were conducted in the safety population (which 
included all patients who received at least one dose 
of caplacizumab or placebo). The time to normal-
ization of the platelet count was compared be-
tween the trial groups with the use of a two-sided 
stratified log-rank test on the basis of a Kaplan–
Meier analysis; the stratification factor was the 
severity of neurologic involvement at baseline 
(i.e., Glasgow Coma Scale score of ≤12 vs. >13). 
The time to normalization of the platelet count 
was also analyzed with the use of a Cox propor-
tional-hazards regression model, with the time 
to normalization of platelet count as a dependent 
variable and treatment group and Glasgow Coma 
Scale category as independent variables (details on 
the Glasgow Coma Scale categories can be found 
in the protocol). The rate ratio (i.e., hazard ratio) 
for normalization of the platelet count estimated 
with the Cox model was reported along with the 
corresponding 95% confidence intervals. (Because 
the time to normalization of the platelet count 
is linked with a positive outcome, “rate ratio” is 
used to describe the result instead of the typical 
“hazard ratio,” with similar interpretation.)
A fixed-sequence approach was applied for 
analyses of the key secondary outcomes that were 
hierarchically ordered on the basis of clinical 
relevance. The first three outcomes were analyzed 
with the use of a Cochran–Mantel–Haenszel test; 
the model included adjustment for baseline sever-
ity of neurologic involvement. The fourth outcome 
was analyzed with the use of a stratified log-rank 
test that was based on a Kaplan–Meier analysis, 
with adjustment for severity of baseline neurologic 
involvement and baseline lactate dehydrogenase 
level.
R esult s
Trial Population
During the period from November 2015 through 
April 2017, a total of 145 patients were random-
ly assigned to receive caplacizumab (72 patients) 
or placebo (73 patients). All the patients received 
the assigned caplacizumab or placebo, except for 
1 patient assigned to the caplacizumab group who 
withdrew consent before receiving the first dose. 
Overall, 108 patients completed the trial (i.e., com-
pleted all scheduled treatment visits and had 
their final follow-up visit), and 36 patients who 
had received at least one dose of caplacizumab 
or placebo discontinued the trial regimen (13 in 
the caplacizumab group and 23 in the placebo 
group). The most common reasons for discontinu-
ation were adverse events, withdrawal of consent, 
and physician decision (Fig. S2 in the Supplemen-
tary Appendix).
Demographic and baseline disease character-
istics were generally similar in the two trial groups 
(Table 1). An imbalance between the groups was 
observed in the percentage of patients with ini-
tial as compared with recurrent TTP episodes at 
presentation; this finding was consistent with 
somewhat more severe disease in the caplacizumab 
group, given that initial TTP episodes tend to be 
more severe at presentation than recurrent epi-
sodes.
ADAMTS13 activity at baseline was below 
10% in 123 patients (85%), which confirmed the 
clinical diagnosis of TTP. For 13 of the 20 pa-
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tients who had ADAMTS13 activity of 10% or 
higher at baseline, the diagnosis was confirmed 
on the basis of a history of TTP or of ADAMTS13 
activity below 10% at other time points during 
the trial. For 7 patients (4 in the caplacizumab 
group and 3 in the placebo group), the diagnosis 
of TTP with severe ADAMTS13 deficiency could 
not be confirmed.
Primary Outcome
The median time to normalization of the platelet 
count on the basis of the Kaplan–Meier analysis 
and a stratified log-rank test was significantly 
shorter in the caplacizumab group than in the 
placebo group (Fig. 1 and Table 2). At any given 
time point, patients who received caplacizumab 
were 1.55 times as likely to have a normalization 
of the platelet count as patients who received 
placebo (rate ratio for normalization of platelet 
count, 1.55; 95% confidence interval [CI], 1.09 
to 2.19; P = 0.01).
Key Secondary Outcomes
During the trial treatment period, a component 
of the composite outcome of TTP-related death, 
recurrence of TTP, or a major thromboembolic 
event occurred in 9 patients (12%) in the capla-
cizumab group and in 36 patients (49%) in the 
placebo group. This difference represented a 74% 
lower incidence with caplacizumab than with pla-
cebo (P<0.001) (Table 2).
During the overall trial period, including the 
28-day follow-up period in which patients were 
no longer receiving caplacizumab or placebo, 
9 patients (12%) in the caplacizumab group, as 
compared with 28 patients (38%) in the placebo 
group, had a recurrence of TTP, which repre-
sented a 67% lower incidence of recurrence with 
caplacizumab than with placebo (P<0.001) (Ta-
ble 2). All recurrences in the placebo group oc-
curred within 30 days (range, 2 to 25) after the 
end of daily plasma exchange, which met the defi-
nition of exacerbations.16 Among the patients in 
the caplacizumab group who had a recurrence, 
3 patients had exacerbations (2 had an exacerba-
tion that was possibly triggered by concurrent in-
fection and 1 had an exacerbation that was re-
lated to nonadherence to caplacizumab); the other 
6 patients had a recurrence that occurred during 
the follow-up period (between 2 and 10 days after 
the end of treatment) and hence were considered 
to have had a relapse. In all 6 of the patients who 
had a relapse, the ADAMTS13 activity level was 
still below 10% when caplacizumab treatment 
was stopped, which indicated unresolved under-
lying autoimmune disease (Fig. 2).
Refractory disease developed in no patients in 
the caplacizumab group and in 3 patients in the 
placebo group (P = 0.06) (Table 2). Normalization 
of the three organ-damage markers (lactate de-
hydrogenase, cardiac troponin I, and serum cre-
atinine) occurred somewhat sooner in patients 
who received caplacizumab than in those who 
received placebo (Table 2, and Fig. S4 in the 
Supplementary Appendix).
Other Outcomes
ADAMTS13 Activity in Relation to Recurrence
A total of 129 patients (65 in the caplacizumab 
group and 64 in the placebo group) had normal-
ization of the platelet count and completed the 
period of daily plasma exchange. In the week 
after daily plasma exchange ended, ADAMTS13 
activity was still severely suppressed (i.e., <10%) 
in 57% of the patients overall (73 of 129 patients) 
— in 60% of the patients in the caplacizumab 
group (39 of 65 patients) and in 53% of the pa-
tients in the placebo group (34 of 64 patients). 
In total, 31 patients (3 in the caplacizumab group 
and 28 in the placebo group) had an exacerbation 
(i.e., recurrence within 30 days after the end of 
daily plasma exchange), 28 of whom (3 in the 
caplacizumab group and 25 in the placebo group) 
had unresolved underlying autoimmune disease, 
with ADAMTS13 activity levels below 10% (Fig. 2A).
Information on the ADAMTS13 activity level 
at the time that administration of caplacizumab 
or placebo was stopped was available for 120 pa-
tients (60 at the end of the period of double-blind 
administration of caplacizumab, 34 at the end of 
the period of double-blind administration of pla-
cebo, and 26 at the end of the period of open-
label administration of caplacizumab). In 29 of 
the 120 patients (24%), ADAMTS13 was still se-
verely deficient at the time that the caplacizumab 
or placebo was stopped. Among these 29 patients, 
9 had a relapse during the follow-up period 
(Fig. 2B).
Health Care Resource Utilization
During the overall treatment period — which 
included, for all patients, the period of double-
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Characteristic
Caplacizumab 
(N = 72)
Placebo 
(N = 73)
Total 
(N = 145)
Demographic and baseline disease characteristics
Mean age (range) — yr 45 (18–77) 47 (21–79) 46 (18–79)
Female sex — no. (%) 49 (68) 51 (70) 100 (69)
Mean body-mass index (range)† 30 (18–53) 30 (19–59) 36 (18–59)
Race — no. (%)‡
White 47 (65) 50 (68) 97 (67)
Black 15 (21) 13 (18) 28 (19)
Asian 4 (6) 0 4 (3)
Other 3 (4) 1 (1) 4 (3)
Data missing 3 (4)  9 (12) 12 (8)
Hispanic or Latino ethnic group — no. (%)‡ 4 (6) 2 (3) 6 (4)
Presenting episode of TTP — no. (%)§
Initial 48 (67) 34 (47) 82 (57)
Recurrent 24 (33) 39 (53) 63 (43)
Median platelet count (range) — per mm3¶‖ 24,000 (3,000–119,000) 25,000 (9,000–133,000) 24,000 (3,000–133,000)
Median lactate dehydrogenase (range) —  
U per liter‖
449 (120–2525) 403 (151–3343) 422 (120–3343)
Median cardiac troponin I (range) — μg per liter‖ 0.09 (0.01–75.96) 0.07 (0.01–7.28) 0.08 (0.01–75.96)
Median serum creatinine (range) — μmol per liter‖ 77 (35–717) 82 (52–482) 80 (35–717)
ADAMTS13 activity — no. (%)‖**
<10% 58 (81) 65 (89) 123 (85)
≥10% 13 (18) 7 (10) 20 (14)
Data missing 1 (<1) 1 (<1) 2 (1)
Glasgow Coma Scale score — no. (%)††
≤12 6 (8) 5 (7) 11 (8)
13 to 15 65 (90) 67 (92) 132 (91)
Data missing 1 (<1) 1 (<1) 2 (1)
Immunosuppressive therapy — no. (%)
Glucocorticoids 69 (96) 71 (97) 140 (97)
Rituximab 28 (39) 35 (48) 63 (43)
Frontline, started by trial day 3 9 (12) 16 (22) 25 (17)
During daily plasma exchange, started after 
trial day 3
3 (4) 7 (10) 10 (7)
After the period of daily plasma exchange 11 (15) 6 (8) 17 (12)
During daily plasma exchange among patients 
who had exacerbation
0 1 (1) 1 (1)
After the period of daily plasma exchange 
among patients who had exacerbation
0 2 (3) 2 (1)
During the follow-up period 5 (7) 3 (4) 8 (6)
Table 1. Demographic and Baseline Disease Characteristics and Concomitant Treatments for TTP in the Intention-to-Treat Population.*
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blind administration of caplacizumab or placebo, 
and, in addition, for patients who had an exacer-
bation and were switched to treatment with open-
label caplacizumab, the period of open-label 
administration of caplacizumab — patients who 
received caplacizumab needed an average of 5.8 
days of plasma-exchange treatment, as compared 
with 9.4 days of plasma-exchange treatment need-
ed by patients in the placebo group, which rep-
resented a 38% shorter duration of such treatment 
with caplacizumab than with placebo. Accord-
ingly, the average volume of plasma exchanged 
was 21.3 liters for patients who received caplaciz-
umab as compared with 35.9 liters for patients 
in the placebo group, which represented a 41% 
lower volume with caplacizumab than with pla-
cebo. Moreover, a 65% shorter duration of care in 
an intensive care unit (mean, 3.4 days vs. 9.7 days) 
and a 31% shorter duration of hospitalization 
(mean, 9.9 days vs. 14.4 days) were also noted 
(Table 2).
Immunogenicity
Drug-induced antibodies to caplacizumab developed 
in 3% of the patients who received caplacizumab. 
No effect on either clinical efficacy or ristocetin 
cofactor activity was observed, and no serious ad-
verse events were reported in these patients.
Safety
The median duration of exposure to caplacizumab 
was longer than the duration of exposure to pla-
Characteristic
Caplacizumab 
(N = 72)
Placebo 
(N = 73)
Total 
(N = 145)
Mycophenolate mofetil 6 (8) 0 6 (4)
Hydroxychloroquine 2 (3) 1 (1) 3 (2)
Bortezomib 2 (3) 0 2 (1)
Cyclophosphamide 1 (1) 1 (1) 2 (1)
Cyclosporin 1 (1) 1 (1) 2 (1)
Other treatments for TTP — no. (%)
Splenectomy
Performed before the start of the trial 0 5 (7) 5 (3)
Performed during the trial 2 (3) 1 (1) 3 (2)
Immune globulin concentrate infusion 4 (6) 0 4 (3)
Immunoadsorption 1 (1) 0 1 (1)
*  There were no significant differences between the groups in the characteristics listed in this table, except as noted. Baseline was defined 
as the period before the first administration of caplacizumab or placebo; all the patients were to have received a single plasma-exchange 
treatment before randomization to caplacizumab or placebo. To convert the values for creatinine to milligrams per deciliter, divide by 
88.4. TTP denotes thrombotic thrombocytopenic purpura.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  Race and ethnic group were determined by the investigator.
§  The difference between the trial groups in the percentage of patients who presented with an initial episode as compared with a recurrent 
episode was significant (P<0.05).
¶  All the patients in the trial had a platelet count of less than 100,000 per cubic millimeter at screening, which met the entry criteria of the 
trial, with the exception of one patient in the placebo group who entered the trial with a platelet count of 100,000 per cubic millimeter; this 
was reported as a major protocol deviation.
‖  Normal ranges used in the trial were as follows: platelet count, 150,000 to 450,000 per mm3; lactate dehydrogenase, 120 to 246 U per liter; 
cardiac troponin I, 0 to 0.059 μmol per liter; serum creatinine, 44 to 97 μmol per liter (0.5 to 1.1 mg per deciliter) (women) and 62 to 115 μmol 
per liter (0.7 to 1.3 mg per deciliter) (men); and ADAMTS13 activity, 50 to 130%.
**  ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) is a von Willebrand factor–cleaving 
protease that leads to platelet consumption in von Willebrand factor–platelet aggregates and microvascular thrombosis. As a result of the 
requirement for previous plasma exchange, baseline ADAMTS13 activity was higher than that measured locally at the time of admission in 
some cases. When available, ADAMTS13 activity levels that were locally measured at the time of admission were obtained, and the lower 
value of the baseline and admission values is represented.
††  The Glasgow Coma Scale score is a measure of neurologic involvement; scores range from 3 to 15, with lower scores indicating worse 
mental status.
Table 1. (Continued.)
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cebo (35 days [range, 1 to 65] vs. 23 days [range, 
2 to 66]). This difference is attributable to the trial 
design, which included a switch to open-label 
caplacizumab in cases in which a patient had a 
recurrence during the double-blind treatment pe-
riod, and to the fact that almost all recurrences 
occurred in the placebo group.
The most commonly reported adverse events 
that occurred in at least 5% of the patients in ei-
ther trial group during the double-blind treatment 
period are listed in decreasing order of relative 
risk (caplacizumab vs. placebo) in Figure 3. Dur-
ing the overall trial period, 68 patients (96%) in 
the caplacizumab group and 66 patients (90%) in 
the placebo group had at least one adverse event 
(excluding adverse events of TTP, which were 
considered to be secondary efficacy outcomes) 
(Table S1 in the Supplementary Appendix).
A total of 4 patients died during the trial, 
including 1 (1%) in the caplacizumab group 
(during the treatment-free follow-up period) and 
3 (4%) in the placebo group (all during the treat-
ment period). All 4 deaths were adjudicated as 
TTP-related. The cause of death in the patient in 
the caplacizumab group was cerebral ischemia 
and was assessed by the investigator as unrelated 
to treatment; the cause of death in the patients in 
the placebo group was worsening massive ische-
mic attack with hemorrhagic transformation in 
1 patient and refractory TTP (specifically, “wors-
ening TTP with coma and death” and “hypoxia 
with bleeding in the lung”) in the 2 other pa-
tients. Serious adverse events (excluding serious 
adverse events of TTP, which were considered to 
be secondary efficacy outcomes) were reported in 
23 patients (32%) in the caplacizumab group and 
in 12 patients (16%) in the placebo group during 
the overall trial period (Table S2 in the Supple-
mentary Appendix). Five patients in the caplaciz-
umab group and 9 patients in the placebo group 
had an adverse event that led to discontinuation 
of the trial regimen.
Bleeding-related adverse events were reported 
in 46 patients (65%) in the caplacizumab group 
and in 35 patients (48%) in the placebo group 
(Table S3 in the Supplementary Appendix). The 
most common such events were epistaxis and 
gingival bleeding; all these events resolved, most 
without intervention. These events were mild or 
moderate in severity in a majority of patients and 
were severe in 3 patients in the caplacizumab 
group (epistaxis, gingival bleeding, and upper gas-
trointestinal hemorrhage in 1 patient each) and 
in 1 patient in the placebo group (hemorrhagic 
transformation stroke). Serious adverse events of 
bleeding were reported in 8 patients (11%) in the 
caplacizumab group and in 1 patient (1%) in the 
placebo group. The most commonly reported se-
rious adverse event of bleeding was epistaxis, 
which occurred in 4 patients in the caplacizumab 
group. One patient received von Willebrand fac-
tor concentrate as the only treatment for resolu-
tion of a severe, serious adverse event of epistaxis. 
No temporal relationship between the occurrence 
of bleeding and the duration of exposure to capla-
cizumab was observed.
Discussion
In this phase 3 trial involving patients with TTP, 
the time to normalization of the platelet count 
was shorter among patients who had received ca-
placizumab than among those who had received 
placebo, presumably because caplacizumab pre-
vented the consumption of platelets in micro-
thrombi. The trial also showed that treatment 
with caplacizumab resulted in a lower incidence 
of a composite of TTP-related death, recurrence 
of TTP, or a major thromboembolic event during 
the trial treatment period and a lower incidence 
of recurrence during the overall trial period than 
placebo.
Exacerbations occurred up to 25 days after the 
Figure 1. Time to Confirmed Normalization of the Platelet Count  
in the Intention-to-Treat Population.
Symbols indicate censored data.
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Outcome
Caplacizumab 
(N = 72)
Placebo 
(N = 73) P Value
Primary outcome
Time to normalization of platelet count
25th Percentile (95% CI) — days 1.75 (1.65–1.87) 1.94 (1.70–2.64)
50th Percentile (95% CI) — days 2.69 (1.89–2.83) 2.88 (2.68–3.56)
75th Percentile (95% CI) — days 2.95 (2.85–3.81) 4.50 (3.78–7.79)
Rate ratio for normalization of platelet count,  
caplacizumab vs. placebo (95% CI)*
1.55 (1.09–2.19) 0.01
Key secondary outcomes
Composite of TTP-related death, recurrence of TTP,  
or major thromboembolic event during the  
double-blind treatment period — no. (%)
 9 (12) 36 (49) <0.001
TTP-related death 0 3 (4)
Recurrence of TTP: exacerbation† 3 (4) 28 (38)
Major thromboembolic event 6 (8) 6 (8)
Recurrence of TTP at any time during the trial — no. (%)†    9 (12) 28 (38) <0.001
During the double-blind treatment period: exacerbation 3 (4) 28 (38)
During the follow-up period: relapse‡ 6 (8) 0
Refractory TTP — no. (%)§ 0 3 (4) 0.06
Median time to normalization of organ-damage markers  
(95% CI) — days
2.86 (1.93–3.86) 3.36 (1.88–7.71)
Other secondary outcomes¶
Number of days of plasma exchange
Mean (95% CI) 5.8 (4.8–6.8) 9.4 (7.8–11.0)
Median (range)  5.0 (1.0–35.0) 7.0 (3.0–46.0)
Volume of plasma exchanged — liters
Mean (95% CI) 21.3 (18.1–24.6) 35.9 (27.6–44.2)
Median (range) 18.1 (5.3–102.2) 26.9 (4.0–254.0)
No. of days of hospitalization
Mean (95% CI) 9.9 (8.5–11.3) 14.4 (12.0–16.9)
Median (range) 9.0 (2.0–37.0) 12.0 (4.0–53.0)
Patients admitted to the intensive care unit — no. (%)‖ 28 (39) 27 (37)
No. of days in the intensive care unit
Mean (95% CI) 3.4 (2.6–4.2) 9.7 (5.3–14.1)
Median (range) 3.0 (1.0–10.0) 5.0 (1.0–47.0)
*  Because an event (time to normalization of the platelet count) in this trial is linked with a positive outcome, “rate ratio” 
for normalization of the platelet count is used to describe the result instead of the typical “hazard ratio,” with similar 
interpretation.
†  Recurrence was defined as a new decrease in the platelet count after initial normalization of the platelet count, necessi-
tating reinitiation of plasma exchange. According to the consensus terminology,16 a recurrence within 30 days after the 
end of daily plasma exchange is considered to be an exacerbation, and a recurrence that occurs more than 30 days after 
the end of daily plasma exchange is considered to be a relapse.
‡  Four of the six patients who had a relapse during the follow-up period had received the maximum allowed extension of 
treatment.
§  Refractory TTP was defined as the lack of a doubling of the platelet count after 4 days of treatment and a lactate dehy-
drogenase level that remained above the upper limit of the normal range.17
¶  These outcomes were assessed during the trial treatment period.
‖  Admission to the intensive care unit for administration of plasma exchange is standard practice at some centers and is 
not necessarily indicative of more severe clinical presentation.
Table 2. Primary and Secondary Efficacy Outcomes in the Intention-to-Treat Population.
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end of plasma exchange, which supports the need 
for treatment with caplacizumab during the pe-
riod in which a patient is at risk (i.e., for at least 
30 days after normalization of the platelet count 
is achieved). In the phase 2 trial, when caplaciz-
umab was stopped, early relapses occurred in a 
subgroup of patients who had persistent severe 
ADAMTS13 deficiency below 10%. On the basis 
of these results, the current trial was designed to 
allow investigators to continue administration of 
caplacizumab or placebo under blinded conditions 
in patients who had evidence of persistent auto-
immune activity (e.g., ADAMTS13 activity <10%) 
at the end of the 30-day period after the last 
plasma exchange. Continuation of caplacizumab 
or placebo was to be accompanied by adjustment 
of immunosuppressive therapy. This approach of 
extending the treatment period was validated, as 
evidenced by the occurrence of fewer relapses in 
this trial than in the phase 2 trial. The relapses 
that did occur were all in patients who still had 
severely suppressed ADAMTS13 activity below 
10%. This finding suggests that monitoring of 
ADAMTS13 activity could be useful in guiding 
not only immunosuppressive treatment18-22 but 
also the continuation of caplacizumab treatment 
beyond 30 days after stopping plasma exchange.
No patient in either the phase 2 trial or the 
current trial died while receiving treatment with 
caplacizumab. In addition, treatment with capla-
cizumab prevented the development of refractory 
disease and consequently the negative outcomes 
that are commonly reported in patients with re-
fractory TTP. Normalization of markers associated 
with organ damage occurred sooner among pa-
tients who received caplacizumab than among 
those who received placebo. The effect of treat-
ment with caplacizumab on the time to normal-
ization of the platelet count and on the incidence 
of recurrence was also reflected in the fewer num-
ber of days of plasma exchange and the shorter 
stays in the hospital and in the intensive care 
unit among patients who received caplacizumab 
than among those who received placebo.
Caplacizumab interferes with von Willebrand 
factor, a key protein in hemostasis. Accordingly, 
it is associated with mucocutaneous bleeding that 
is similar to that observed in patients with von 
Willebrand’s disease.23 Safety results in the current 
trial were consistent with those reported previ-
ously,13 including an increased risk of bleeding.
Over the past two decades, despite a better un-
derstanding of the pathophysiological characteris-
tics of TTP,24 treatment outcomes have not changed 
substantially, with recent mortality rates reported 
to be as high as 20%.25 Death occurs primarily 
during the acute phase, as a result of uncontrolled 
formation of microvascular thrombi. The current 
treatments — plasma exchange and immunosup-
pression — replenish functional ADAMTS13 en-
zyme and control the underlying autoimmune 
disease but do not directly address the microvas-
cular thrombosis. Caplacizumab blocks adhesion 
of von Willebrand factor multimers to platelets, 
a step in the formation of these thrombi.
Overall, caplacizumab showed value when add-
ed to the standard treatment for acquired TTP. 
Figure 2. Recurrence Status According to ADAMTS13 Activity  
in the Intention-to-Treat Population.
ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin 
type 1 motif, member 13) is a von Willebrand factor–cleaving protease that 
leads to platelet consumption in von Willebrand factor–platelet aggregates 
and microvascular thrombosis. Panel A shows individual-patient data on 
exacerbation status during the trial treatment period. Panel B shows indi-
vidual-patient data on relapse status during the follow-up period (i.e., after 
the end of the treatment period). Recurrences are termed exacerbations if 
they occur within 30 days after the last plasma exchange (PE) and relapses 
if they occur more than 30 days after the last PE.
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This added value was associated with a higher in-
cidence of low-grade mucosal bleeding than that 
with placebo.
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